Restylane

Restylane is a family of ready-to-use, cross-linked hyaluronic acid gels, not one formulation or one set of indications. In the United States, the family spans nine named products. They share bacterial-source HA at 20 mg/mL, but differ in lidocaine, gel technology, presentation details, labeled anatomy, and placement.

Market represented: United States
The US portfolio and current instructions for use (IFUs) were checked together because a portfolio page can lag a newly approved indication. In particular, FDA added a chin indication for Restylane Lyft with Lidocaine on November 4, 2025 and a temple-hollowing indication for Restylane Contour on March 20, 2026 (FDA Lyft approval letter 🔗; FDA Contour PMA supplement 🔗).

US family at a glance

Formulation and presentation

Exact US product	Documented formulation	Lidocaine	Galderma technology grouping
Restylane 🔗	Streptococcus-derived HA, BDDE-cross-linked, 20 mg/mL in phosphate-buffered saline (PBS), pH 7	None stated in this product	NASHA family context
Restylane-L 🔗	Streptococcus-derived HA, BDDE-cross-linked, 20 mg/mL in PBS, pH 7	0.3% (3 mg/mL)	NASHA
Restylane Lyft with Lidocaine 🔗	Streptococcus-derived HA, BDDE-cross-linked, 20 mg/mL in PBS, pH 7	0.3%	NASHA
Restylane Silk 🔗	Streptococcus-derived HA, BDDE-cross-linked, 20 mg/mL in PBS, pH 7	0.3%	NASHA
Restylane Eyelight 🔗	Streptococcus-derived HA, BDDE-cross-linked, 20 mg/mL in PBS, pH 7	0.3%	NASHA
Restylane Refyne 🔗	Cross-linked bacterial-origin sodium hyaluronate, 20 mg/mL in PBS, pH 7; the current IFU does not name the crosslinker	3 mg/mL	XpresHAn
Restylane Defyne 🔗	BDDE-cross-linked sodium hyaluronate, 20 mg/mL in PBS, pH 7	3 mg/mL	XpresHAn
Restylane Kysse 🔗	Bacterial-origin HA, BDDE-cross-linked, 20 mg/mL in PBS, pH 7	3 mg/mL	XpresHAn
Restylane Contour 🔗	Bacterial-origin HA, BDDE-cross-linked sodium hyaluronate, 20 mg/mL in PBS, pH 7	3 mg/mL	XpresHAn

The Refyne description of bacterial-origin cross-linked sodium hyaluronate is documented in FDA’s original P140029 SSED; because the current IFU does not identify its crosslinker, none is supplied here by analogy with the sibling gels (FDA Refyne and Defyne SSED 🔗). The technology assignments follow Galderma’s current US description: Restylane-L, Lyft, Silk, and Eyelight are identified as NASHA products, while Refyne, Defyne, Kysse, and Contour are identified as XpresHAn products (Restylane US science and technology 🔗). The non-lidocaine Restylane formulation belongs to the historically named non-animal stabilized HA context, but the current US technology list names Restylane-L rather than separately listing both lidocaine versions.

The products are supplied as sterile, single-use treatment syringes with the volume and co-packed administration tool identified on the exact syringe label and carton. Current IFUs document disposable or individual prefilled syringes; they do not support borrowing a syringe volume or needle/cannula configuration from a sibling variant. Contour’s current FDA SSED, for example, documents a prefilled plastic syringe and two co-packed 27 G needles, while Silk’s IFU documents a disposable glass syringe and co-packed 30 G needles (FDA Contour SSED 🔗; Restylane Silk IFU 🔗).

Labeled use and placement

All entries below concern US labeling for adults over 21. The table condenses the label; it is not an injection protocol.

Exact US product	Current labeled objective	Labeled placement context
Restylane / Restylane-L	Moderate-to-severe facial wrinkles and folds, such as nasolabial folds; lip augmentation	Mid-to-deep dermis for folds; submucosal for lips (Restylane IFU 🔗; Restylane-L IFU 🔗)
Restylane Lyft with Lidocaine	Moderate-to-severe facial folds and wrinkles; cheek augmentation and age-related midface contour deficiency; dorsal-hand volume deficit; mild-to-moderate chin retrusion	Deep dermis to superficial subcutis for folds; subcutaneous to supraperiosteal for cheek/midface; subcutaneous dorsal hand; subcutaneous and/or supraperiosteal chin (current US IFU 🔗)
Restylane Silk	Lip augmentation; perioral rhytids	Submucosal lip; mid-to-deep dermis for rhytids (current US IFU 🔗)
Restylane Kysse	Lip augmentation; upper perioral rhytids	Submucosal lip; mid-dermis to subcutaneous layer for perioral rhytids and philtral column (current US IFU 🔗)
Restylane Refyne	Moderate-to-severe facial wrinkles and folds, such as nasolabial folds	Mid-to-deep dermis (current US IFU 🔗)
Restylane Defyne	Moderate-to-severe deep facial wrinkles and folds; mild-to-moderate chin retrusion	Mid-to-deep dermis for folds; subcutaneous and/or supraperiosteal chin (current US IFU 🔗)
Restylane Contour	Cheek augmentation and midface contour deficiency; temple hollowing	Subcutaneous or supraperiosteal cheek/midface; supraperiosteal or subdermal temple, depending on the labeled approach (current US IFU 🔗; FDA temple-hollowing SSED 🔗)
Restylane Eyelight	Infraorbital hollowing	Supraperiosteal plane (current US IFU 🔗)

The exact indication matters more than a shorthand such as lip filler, dynamic filler, or structural filler. A technology group does not grant every member the same anatomy, plane, tool, or evidence endpoint.

NASHA and XpresHAn / OBT

NASHA is Galderma’s name for its non-animal stabilized hyaluronic acid technology. XpresHAn is the name Galderma uses in the United States for a second manufacturing platform that it calls Optimal Balance Technology (OBT) globally. Galderma expressly describes XpresHAn as globally referred to as OBT; the two names should therefore be treated as regional company terminology, not as separate universal scientific classes (Galderma Defyne announcement 🔗).

Within the current US family, the technology labels divide products into related manufacturing contexts, but do not make their finished gels equivalent. Refyne, Defyne, Kysse, and Contour all use the XpresHAn name and share the same stated HA concentration, yet their indications and placement contexts differ. The NASHA group likewise includes products intended for folds, lips, cheeks, hands, chin, and infraorbital hollows.

Manufacturer statements about firmness, flexibility, support, movement, or tissue integration are attributed technology descriptions. They should not be converted into an anatomy-by-product rule, safety ranking, or clinical-performance hierarchy. Use Formulation and Gel Architecture to separate a branded platform from the complete finished formulation, and Rheology and Physical Properties before comparing any G′, flexibility, cohesivity, or swelling result.

Regional names are not automatic aliases

The table above is deliberately US-specific. Galderma’s global portfolio uses OBT terminology and includes names not present in the current US family list. In one documented relationship, Galderma states that US Restylane Contour is marketed outside the United States as Restylane Volyme. That company statement is useful naming context, but it does not establish that every Volyme presentation, label, or approval is identical in every country (Galderma Contour announcement 🔗).

Restylane SHAYPE provides the opposite boundary: Galderma announced Canadian regulatory approval for this NASHA HD product in January 2024, but it is not listed in the current US Restylane family and should not be added to a US matrix without an FDA approval record (Galderma SHAYPE announcement 🔗; current US portfolio 🔗).

Before mapping a non-US product to this page, verify the local product name, concentration, lidocaine, syringe, IFU, indication, approval holder, and commercial availability.

Company and regulatory roles

Role	Supported US relationship
Brand and US commercial portfolio	Galderma / Galderma Laboratories, L.P.
Legal manufacturer in current US IFUs	Q-Med AB, Uppsala, Sweden
Manufactured for	Galderma Laboratories, L.P., Dallas, Texas
FDA PMA applicant	Q-Med AB appears in the governing P040024 and P140029 records; some FDA overview pages display Galderma Laboratories, L.P. as applicant/contact for later supplements
Local distributor	Verify from the exact current product IFU and authorized US channel

The manufacturer relationship is stated directly in current US labeling; for example, the Restylane, Contour, Defyne, Kysse, Lyft, Silk, and Eyelight IFUs identify Q-Med AB as manufacturer and Galderma Laboratories, L.P. as the entity for which the product is manufactured (Restylane IFU 🔗; Contour IFU 🔗; Eyelight IFU 🔗). FDA records identify Q-Med AB as applicant for the 2026 Contour and 2025 Lyft indication supplements (Contour PMA 🔗; Lyft approval letter 🔗). These US roles should not be copied to another market without its own label or registration record.

Safety and hyaluronidase boundary

Across the current labels, common expected local responses include combinations of swelling, redness, tenderness, pain, bruising, itching, and palpable lumps or bumps. Contraindications and precautions vary by exact variant, but recurrent label themes include severe allergy or anaphylaxis history, allergy to gram-positive bacterial proteins, lidocaine or amide-anesthetic allergy for lidocaine-containing variants, active inflammation or infection at the site, and bleeding-related considerations. Read the exact current IFU rather than treating this summary as a shared family label.

All facial soft-tissue filler injections carry a risk of inadvertent vascular introduction. Current Restylane labels warn of embolization, vascular occlusion, ischemia or infarction, skin necrosis, visual impairment or blindness, and cerebral ischemic events, and direct prompt medical attention when relevant warning signs occur (Restylane-L IFU 🔗; Restylane Eyelight IFU 🔗).

Hyaluronidase appears in Restylane post-market labeling as one of several treatments reported when intervention was required. That observation does not establish a uniform dose, complete removal, or equivalent response across the nine gels (Restylane-L IFU 🔗). Hyaluronidase response depends on the exact gel, enzyme preparation, exposure, amount, timing, anatomy, and clinical objective. Elective correction, suspected vascular compromise, infection, and inflammatory presentations must not be collapsed into one dissolving scenario.

Nearby reference pages

Hyaluronic Acid Fillers explains why the family name and HA concentration are incomplete product identities.
Formulation and Gel Architecture provides the framework for reading BDDE crosslinking, lidocaine, and product presentation.
Rheology and Physical Properties explains why method-dependent measurements should not become a Restylane variant ranking.
Collagen Stimulators separates ready-to-use HA gels from reconstituted or particle-based injectable systems.